CTRI/2017/10/010053
Completed
Phase 4
Post Marketing Surveillance of Rasaushadhis used in Shwasa Roga and Quality Assurance of Shwaskuthara Rasa
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: J00-J99- Diseases of the respiratory systemHealth Condition 2: null- Patients suffering from Asthma (Shwasa Roga)
- Sponsor
- All India Institute of Ayurveda
- Enrollment
- 512
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients of Shwasa Roga (Asthma)
Exclusion Criteria
- •Patients suffering from Diabetes, Hypertension, Cardiac and Renal disorders
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A Survey of Darvadstrocel in People with Crohn's DiseaseCrohn's DiseaseJPRN-jRCT2033210424Contact for Clinical Trial Information275
Recruiting
Phase 4
A post marketing study to evaluate safety and effectiveness of Remogliflozin and Remogliflozin-Metformin Combination in treatment of Diabetes patientsHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2019/11/022062Glenmark Pharmaceuticals Ltd
Completed
Not Applicable
postmarketing surveillance For Investigating success in achieving clinical and functional Remission and Sustaining efficacy with Tocilizumab in BIOlogics naive RA patientsPatients with rheumatoid arthritis who have been diagnosed based on the 2010 ACR/EULAR new classification criteria for RA Patients who have no previous medical history of biological agents for RA Patients whose disease activity is DAS28>=3.2 at baselineJPRN-UMIN000006914Chugai Pharmaceutical Co. Ltd.700
Active, not recruiting
Not Applicable
roLift System post-marketing surveillanceBenign prostatic hyperplasia with lower urinary tract symptoms (LUTS)BPH, LUTS110200JPRN-jRCT2032220377Kadono Yoshihiko200
Completed
Phase 4
Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety & Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomnia in Actual Field Conditions Of Use.CTRI/2020/03/023789AN Pharmacia Laboratories Pvt ltd200